Comparative humoral response of mRNA and inactivated vaccines against COVID-19 in healthy adults aged 60 years and older

Basit Öğe Kaydı
dc.authoridOTLU, BARIS/0000-0002-6220-0521
dc.authoridSüer, Kaya/0000-0002-2565-3425
dc.authoridguvenir, meryem/0000-0002-9702-9947
dc.authorwosidYuruker, Ozel/GWU-5255-2022
dc.authorwosidOTLU, BARIS/ABI-5532-2020
dc.authorwosidSüer, Kaya/GNM-8453-2022
dc.authorwosidguvenir, meryem/G-9669-2018
dc.contributor.authorGuvenir, Meryem
dc.contributor.authorYuruker, Ozel
dc.contributor.authorYetkin, Osman
dc.contributor.authorSuer, Kaya
dc.contributor.authorOtlu, Baris
dc.date.accessioned2024-08-04T20:53:31Z
dc.date.available2024-08-04T20:53:31Z
dc.date.issued2023
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIntroduction: A vaccine against coronavirus disease 2019 (COVID-19) is critically needed for older adults because of the increased morbidity and mortality rates.Methodology: In this prospective study, we analysed the titre magnitude of the IgG antibodies directed against the SARS-CoV-2 Spike Protein S1 (S1-RBD) antigen in both CoronaVac and Pfizer-BioNTech groups. The samples were tested to detect antibodies that bind to the receptor -binding domain of the spike protein of SARS-CoV-2 using the Enzyme-Linked Immunosorbent Assay (ELISA) technique with SARS-CoV-2 IgG II Quant. The cut-off value was > 50 AU/mL. GraphPad Prism software was used. Statistical significance was defined atp < 0.05.Results: The CoronaVac group (12 females, 13 males) had a mean age of 69.64 +/- 1.38 years. The Pfizer-BioNTech group (13 males, 12 females) had a mean age of 72.36 +/- 1.44 years. The anti-S1-RBD titre decrease rate from the 1st to the 3rd month for CoronaVac and Pfizer-BioNTech groups was 74.31% and 86.48%, respectively. There was no statistically significant difference in the antibody titre between the 1st month and 3rd month for the CoronaVac group. However, there was a significant difference between the 1st and 3rd month in the Pfizer-BioNTech group. In addition, there was no statistically significant difference in the genders between the 1st and 3rd month of the antibody titres for both the CoronaVac Pfizer-BioNTech group.Conclusions: The levels of anti-S1-RBD, the preliminary outcome data of our study, represents one piece of the puzzle of humoral response and duration of vaccination protection.en_US
dc.identifier.doi10.3855/jidc.16842
dc.identifier.endpage181en_US
dc.identifier.issn1972-2680
dc.identifier.issue2en_US
dc.identifier.pmid36897897en_US
dc.identifier.scopus2-s2.0-85150079402en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage178en_US
dc.identifier.urihttps://doi.org/10.3855/jidc.16842
dc.identifier.urihttps://hdl.handle.net/11616/101226
dc.identifier.volume17en_US
dc.identifier.wosWOS:000952839700005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherJ Infection Developing Countriesen_US
dc.relation.ispartofJournal of Infection in Developing Countriesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectvaccineen_US
dc.subjecthumoral immunityen_US
dc.subjectcellular immunityen_US
dc.subjectCyprusen_US
dc.titleComparative humoral response of mRNA and inactivated vaccines against COVID-19 in healthy adults aged 60 years and olderen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu